Experimental evidence for a severe proarrhythmic potential of levosimendan. (1st February 2017)
- Record Type:
- Journal Article
- Title:
- Experimental evidence for a severe proarrhythmic potential of levosimendan. (1st February 2017)
- Main Title:
- Experimental evidence for a severe proarrhythmic potential of levosimendan
- Authors:
- Frommeyer, Gerrit
Kohnke, Anja
Ellermann, Christian
Dechering, Dirk G.
Kochhäuser, Simon
Pott, Christian
Fehr, Michael
Eckardt, Lars - Abstract:
- Abstract: Background: The calcium sensitizer levosimendan is established for therapy of acutely decompensated congestive heart failure. Clinical experience suggests a possible proarrhythmic potential. The aim of the present study was to assess possible proarrhythmic effects and underlying electrophysiological mechanisms. Methods and results: Ten rabbit hearts were isolated and Langendorff-perfused. Thereafter, levosimendan was infused in 3 concentrations (0.5, 1, and 2 μM). Eight endo - and epicardial monophasic action potentials and a 12-lead ECG showed a dose-dependent reduction of QT interval (0.5 μM: − 27 ms, 1 μM:-33 ms, 2 μM: − 77 ms; p < 0.05) and action potential duration at 90% of repolarization (APD90 ; 0.5 μM: − 12 ms, 1 μM: − 12 ms, 2 μM: − 20 ms). There was no significant increase in dispersion of repolarization. The described abbreviation of myocardial repolarization was accompanied by a significant decrease of effective refractory period (ERP; 0.5 μM: − 16 ms, 1 μM: − 20 ms, 2 μM: − 27 ms; p < 0.05). Under baseline conditions, ventricular fibrillation was inducible by programmed stimulation and aggressive burst stimulation in 3 of 10 hearts (4 episodes). After application of 1 μM levosimendan, 8 of 10 control hearts were inducible (27 episodes). Of note, in 8 of 10 hearts after infusion of up to 2 μM levosimendan, incessant ventricular fibrillation that could not be terminated by multiple external defibrillations occurred. Conclusion: In the present study,Abstract: Background: The calcium sensitizer levosimendan is established for therapy of acutely decompensated congestive heart failure. Clinical experience suggests a possible proarrhythmic potential. The aim of the present study was to assess possible proarrhythmic effects and underlying electrophysiological mechanisms. Methods and results: Ten rabbit hearts were isolated and Langendorff-perfused. Thereafter, levosimendan was infused in 3 concentrations (0.5, 1, and 2 μM). Eight endo - and epicardial monophasic action potentials and a 12-lead ECG showed a dose-dependent reduction of QT interval (0.5 μM: − 27 ms, 1 μM:-33 ms, 2 μM: − 77 ms; p < 0.05) and action potential duration at 90% of repolarization (APD90 ; 0.5 μM: − 12 ms, 1 μM: − 12 ms, 2 μM: − 20 ms). There was no significant increase in dispersion of repolarization. The described abbreviation of myocardial repolarization was accompanied by a significant decrease of effective refractory period (ERP; 0.5 μM: − 16 ms, 1 μM: − 20 ms, 2 μM: − 27 ms; p < 0.05). Under baseline conditions, ventricular fibrillation was inducible by programmed stimulation and aggressive burst stimulation in 3 of 10 hearts (4 episodes). After application of 1 μM levosimendan, 8 of 10 control hearts were inducible (27 episodes). Of note, in 8 of 10 hearts after infusion of up to 2 μM levosimendan, incessant ventricular fibrillation that could not be terminated by multiple external defibrillations occurred. Conclusion: In the present study, acute infusion of levosimendan resulted in an abbreviation of ventricular repolarization and a reduction of ERP. This led to a significantly elevated inducibility of ventricular fibrillation. In 8 of 10 hearts, incessant ventricular fibrillation occurred. These results suggest a proarrhythmic effect of levosimendan and might explain an increased mortality that coincided levosimendan treatment in a few small clinical studies. … (more)
- Is Part Of:
- International journal of cardiology. Volume 228(2017)
- Journal:
- International journal of cardiology
- Issue:
- Volume 228(2017)
- Issue Display:
- Volume 228, Issue 2017 (2017)
- Year:
- 2017
- Volume:
- 228
- Issue:
- 2017
- Issue Sort Value:
- 2017-0228-2017-0000
- Page Start:
- 583
- Page End:
- 587
- Publication Date:
- 2017-02-01
- Subjects:
- Levosimendan -- Therapeutic safety -- Ventricular refractory period -- Ventricular fibrillation
Cardiology -- Periodicals
Electronic journals
616.12 - Journal URLs:
- http://www.clinicalkey.com/dura/browse/journalIssue/01675273 ↗
http://www.sciencedirect.com/science/journal/01675273 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.ijcard.2016.11.251 ↗
- Languages:
- English
- ISSNs:
- 0167-5273
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4542.158000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 7966.xml